bluebird bio Company Profile (NASDAQ:BLUE)

About bluebird bio

bluebird bio logobluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLUE
  • CUSIP:
Key Metrics:
  • Previous Close: $76.55
  • 50 Day Moving Average: $70.32
  • 200 Day Moving Average: $62.80
  • 52-Week Range: $37,303,000.00 - $35.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.25
  • P/E Growth: -0.05
  • Market Cap: $3129.10B
  • Outstanding Shares: 37,303,000
  • Beta: 2.15
  • Net Margins: -3,941.72%
  • Return on Equity: -30.79%
  • Return on Assets: -24.93%
  • Current Ratio: 9.01%
  • Quick Ratio: 9.01%
Additional Links:
Companies Related to bluebird bio:

Analyst Ratings

Consensus Ratings for bluebird bio (NASDAQ:BLUE) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.69)
Consensus Price Target: $87.54 (13.54% upside)

Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
DateFirmActionRatingPrice TargetDetails
2/6/2017Roth CapitalReiterated RatingBuy -> Neutral$87.00 -> $71.00View Rating Details
2/3/2017Maxim GroupSet Price TargetBuy$87.00View Rating Details
1/10/2017Jefferies Group LLCReiterated RatingBuy$88.00View Rating Details
12/10/2016Cantor FitzgeraldReiterated RatingSellView Rating Details
12/7/2016J P Morgan Chase & CoReiterated RatingBuy$120.00View Rating Details
12/4/2016Bank of America CorpReiterated RatingNeutral$68.00View Rating Details
12/1/2016Leerink SwannBoost Price TargetOutperform$80.00 -> $85.00View Rating Details
12/1/2016WedbushReiterated RatingOutperform$95.00View Rating Details
12/1/2016BMO Capital MarketsSet Price TargetHold$61.00 -> $83.00View Rating Details
12/1/2016BTIG ResearchReiterated RatingBuy$83.00View Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00View Rating Details
11/24/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details
10/17/2016Cowen and CompanyReiterated RatingOutperformView Rating Details
10/15/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$135.00View Rating Details
10/14/2016SunTrust Banks, Inc.Reiterated RatingBuyView Rating Details
5/5/2016Wells Fargo & CompanyReiterated RatingBuyView Rating Details
12/7/2015Morgan StanleyDowngradeOverweight -> Equal Weight$143.00 -> $69.00View Rating Details
11/5/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperform$162.00View Rating Details
(Data available from 2/19/2015 forward)


Earnings History for bluebird bio (NASDAQ:BLUE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.61)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.57)($0.67)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.50)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for bluebird bio (NASDAQ:BLUE)
Current Year EPS Consensus Estimate: $-7.02 EPS
Next Year EPS Consensus Estimate: $-7.52 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 201610($1.38)($0.92)($1.21)
Q2 201610($1.56)($0.99)($1.36)
Q3 20168($1.71)($1.28)($1.53)
Q4 20168($2.11)($1.39)($1.73)
Q1 20173($2.08)($1.56)($1.88)
Q2 20173($2.10)($1.60)($1.93)
Q3 20173($2.15)($1.65)($1.98)
Q4 20173($2.22)($1.71)($2.00)
(Data provided by Zacks Investment Research)


Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for bluebird bio (NASDAQ:BLUE)
Insider Ownership Percentage: 3.50%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.00View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.52View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.50View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.72View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.00View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.00View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.00View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.90View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.00View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.12View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.28View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.00View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.12View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.00View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.00View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.00View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.00View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.00View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for bluebird bio (NASDAQ:BLUE)
News IconTarget Price Review & Stock Update on bluebird bio, Inc. (NASDAQ:BLUE) - Rockville Register (NASDAQ:BLUE) - February 19 at 3:44 PM
News IconGene therapy appears effective in patients with transfusion-dependent beta-thalassemia (NASDAQ:BLUE) - February 18 at 10:00 AM logoForm 4 bluebird bio, Inc. For: Feb 15 Filed by: Mandell James (NASDAQ:BLUE) - February 18 at 10:00 AM logoInsider Trading Activity bluebird bio, Inc. (NASDAQ:BLUE) – Insider Sold 3,772 shares of Stock (NASDAQ:BLUE) - February 18 at 10:00 AM logoInsider Trading Activity bluebird bio, Inc. (NASDAQ:BLUE) – Director Sold 850 shares of Stock - Market Exclusive (NASDAQ:BLUE) - February 17 at 6:12 PM logoForm 4 bluebird bio, Inc. For: Feb 15 Filed by: Mandell James - (NASDAQ:BLUE) - February 17 at 6:12 PM logoBluebird Bio: Set To Fly Even Higher? - Seeking Alpha (NASDAQ:BLUE) - February 17 at 6:12 PM logoThese 4 Stocks Are Breaking Out (NASDAQ:BLUE) - February 16 at 4:02 PM
News IconEPS Of bluebird bio, Inc. (NASDAQ:BLUE) At $-1.85 - Stock Observer (NASDAQ:BLUE) - February 16 at 7:55 AM logoThree Biotechs With Bullish Basing Patterns (NASDAQ:BLUE) - February 16 at 7:55 AM logoBRIEF-Omega Advisors cuts share stake in Alphabet, Microsoft; dissolves in Chesapeake Energy (NASDAQ:BLUE) - February 14 at 9:30 PM
News IconNews Impact Score Of bluebird bio, Inc. (NASDAQ:BLUE) At 100 - Stock Observer (NASDAQ:BLUE) - February 14 at 4:29 PM
News IconDigging Deeper into Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Baldwin Journal (NASDAQ:BLUE) - February 14 at 4:29 PM logobluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Termination of a Material Definitive Agreement - Market Exclusive (NASDAQ:BLUE) - February 14 at 4:29 PM logoCooperman's Omega Advisors: Out With Chesapeake; In With Amazon, Bluebird (NASDAQ:BLUE) - February 14 at 4:29 PM logoBLUEBIRD BIO, INC. : Termination of a Material Definitive Agreement (form 8-K) (NASDAQ:BLUE) - February 13 at 4:27 PM logoBLUEBIRD BIO, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement (NASDAQ:BLUE) - February 13 at 4:27 PM
News IconEye on the Numbers for bluebird bio, Inc. (NASDAQ:BLUE) - Piedmont Register (NASDAQ:BLUE) - February 9 at 9:10 PM
News IconChecking the Charts on Shares of Bluebird Bio Inc. (BLUE) - Benton Bulletin (NASDAQ:BLUE) - February 9 at 9:10 PM logoWhy bluebird bio Stock Surged 20.7% Higher in January (NASDAQ:BLUE) - February 9 at 4:10 PM
News IconNews Impact Score Of bluebird bio, Inc. (NASDAQ:BLUE) At 75 ... - Stock Observer (NASDAQ:BLUE) - February 7 at 10:00 PM logoBlueBird Bio Wounded After Roth Downgrade (NASDAQ:BLUE) - February 6 at 3:59 PM logoBluebirdbio downgraded by ROTH Capital (NASDAQ:BLUE) - February 6 at 3:59 PM
News Iconbluebird bio Inc BLUE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:BLUE) - February 4 at 2:13 AM logobluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Other Events - Market Exclusive (NASDAQ:BLUE) - February 3 at 9:11 PM logobluebird bio Announces First Patient Treated with LentiGlobinTM ... - Business Wire (press release) (NASDAQ:BLUE) - February 3 at 9:11 PM logoBLUEBIRD BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:BLUE) - February 3 at 4:08 PM logoForm 8-K bluebird bio, Inc. For: Feb 03 (NASDAQ:BLUE) - February 3 at 4:08 PM logobluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product ... (NASDAQ:BLUE) - February 3 at 4:08 PM logobluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease (NASDAQ:BLUE) - February 3 at 4:08 PM logoSKECHERS USA, Inc. : to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 9th (NASDAQ:BLUE) - February 2 at 9:08 PM logoForm 4 bluebird bio, Inc. For: Jan 27 Filed by: Davidson David - (NASDAQ:BLUE) - February 2 at 2:15 AM logoBluebird Bio Looks Set to Soar Upward (NASDAQ:BLUE) - January 31 at 4:17 PM
News IconStock Watch: Focusing in on bluebird bio, Inc. (NASDAQ:BLUE) - The Tribune (NASDAQ:BLUE) - January 30 at 3:50 PM logoNovartis Signals Growing Ambitions for CAR-T Cancer Treatments (NASDAQ:BLUE) - January 30 at 1:58 AM
News IconEarnings Analysis & Update for bluebird bio, Inc. (NASDAQ:BLUE)? - Aiken Advocate (NASDAQ:BLUE) - January 26 at 9:44 PM
News Iconbluebird bio, Inc. (NASDAQ:BLUE) Quarterly EPS Projection At $-1.85 - Stock Observer (NASDAQ:BLUE) - January 26 at 2:52 AM
News IconEarnings in Full Force, Analysts Take Aim at bluebird bio, Inc. (NASDAQ:BLUE) - Wall Street Beacon (NASDAQ:BLUE) - January 26 at 2:52 AM logobluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : January 24, 2017 (NASDAQ:BLUE) - January 24 at 4:28 PM logobluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : January 23, 2017 (NASDAQ:BLUE) - January 23 at 3:38 PM logoForm SC 13G/A bluebird bio, Inc. Filed by: BAILLIE GIFFORD & CO - (NASDAQ:BLUE) - January 20 at 10:03 PM logoForm SC 13G/A bluebird bio, Inc. Filed by: BAILLIE GIFFORD & CO (NASDAQ:BLUE) - January 20 at 5:01 PM logoCommit To Purchase bluebird bio At $45, Earn 22.2% Using Options - Nasdaq (NASDAQ:BLUE) - January 19 at 8:38 PM
News IconWhat is the Sell-side Saying About bluebird bio, Inc. (NASDAQ:BLUE)? - Aiken Advocate (NASDAQ:BLUE) - January 19 at 3:37 PM logoVetr Crowd Upgrades Bluebird After Trump Presser (NASDAQ:BLUE) - January 11 at 9:21 PM
News IconNews Impact Score Of bluebird bio, Inc. (NASDAQ:BLUE) Set At 0 - Stock Observer (NASDAQ:BLUE) - January 10 at 4:32 PM
News IconInside Transaction: David Davidson Unloaded 923 Shares of bluebird bio Inc (NASDAQ:BLUE) (NASDAQ:BLUE) - January 9 at 10:03 PM logoBLUEBIRD BIO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan (NASDAQ:BLUE) - January 9 at 5:02 PM
News IconUncertain future will certainly be a challenge for biopharma (NASDAQ:BLUE) - January 6 at 9:20 PM
News IconBiotech Stocks: List of Top 10 Biotech Companies to Watch in 2017 (NASDAQ:BLUE) - January 6 at 4:18 PM


What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?

16 analysts have issued twelve-month target prices for bluebird bio's stock. Their predictions range from $37.00 to $135.00. On average, they expect bluebird bio's share price to reach $87.54 in the next year.

When will bluebird bio announce their earnings?

bluebird bio is scheduled to release their next quarterly earnings announcement on Wednesday, February, 22nd 2017.

What are analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:

  • According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (2/9/2017)

  • Jefferies Group LLC analysts commented, "We seek to update our research as appropriate, but various regulations may prevent us from doing so." (1/10/2017)

Who owns bluebird bio stock?

bluebird bio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (16.32%), Baillie Gifford & Co. (13.84%), State Street Corp (4.16%), Franklin Resources Inc. (2.48%), Eventide Asset Management LLC (1.58%) and Arrowpoint Asset Management LLC (1.22%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, Mitchell H Finer, Nick Leschly and Philip D Gregory.

Who sold bluebird bio stock? Who is selling bluebird bio stock?

bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Franklin Resources Inc., State Street Corp, Allianz Asset Management AG, Clarius Group LLC, Guggenheim Capital LLC, Van ECK Associates Corp and Century Capital Management LLC. Company insiders that have sold bluebird bio stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole and Philip D Gregory.

Who bought bluebird bio stock? Who is buying bluebird bio stock?

bluebird bio's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Alyeska Investment Group L.P., Baillie Gifford & Co., Frontier Capital Management Co. LLC, Deerfield Management Co., ARK Investment Management LLC, Arrowpoint Asset Management LLC and Highland Capital Management LP.

How do I buy bluebird bio stock?

Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of bluebird bio stock cost?

One share of bluebird bio stock can currently be purchased for approximately $77.10.

bluebird bio (NASDAQ:BLUE) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Earnings History Chart

Earnings by Quarter for bluebird bio (NASDAQ:BLUE)

Dividend History Chart

Dividend Payments by Quarter for bluebird bio (NASDAQ:BLUE)

Last Updated on 2/19/2017 by Staff